- Dosage: 900mg
- Volume: 7 ml vial
- Packaging: 10 vials/tray/box*200/carton
- Shelf Life: 36 months
Package:
Product Description
Product Overview
Lysine Acetylsalicylate Injection 900mg/7mL is a sterile, aqueous solution of lysine acetylsalicylate intended for parenteral administration. Each 7mL ampoule contains 900mg of lysine acetylsalicylate, equivalent to approximately 500mg of acetylsalicylic acid (aspirin). Lysine acetylsalicylate is the water-soluble DL-lysine salt of acetylsalicylic acid, which allows for parenteral administration of acetylsalicylic acid in situations where oral administration is not feasible or when rapid onset of action is desired. It exhibits the pharmacological properties of acetylsalicylic acid, including analgesic, antipyretic, anti-inflammatory, and antiplatelet activities, and is widely used for the short-term management of pain, fever, and inflammatory conditions, as well as in situations where parenteral antiplatelet therapy is required.
Lysine Acetylsalicylate Injection 7ml:900mg Ampoule: What the Published Guidance Says
The three non-opioid analgesics named on the WHO Model List — paracetamol, ibuprofen and acetylsalicylic acid — in the full range of oral, rectal and injectable presentations, plus the wider NSAID family.
Lysine Acetylsalicylate Injection 7ml:900mg Ampoule sits in the Analgesics & NSAIDs range. The notes below are the ones that most often change a specification, a label or a tender submission.
- Paracetamol is an antipyretic and analgesic — not an anti-inflammatory The Model List carries a footnote stating paracetamol is not recommended for anti-inflammatory use due to lack of proven benefit to that effect. Marketing copy that positions paracetamol as an anti-inflammatory is inconsistent with the WHO listing. WHO Model List of Essential Medicines, 24th List (2025) — report of the 25th WHO Expert Committee (TRS 1064)
- The Model List specifies the exact presentations Section 2.1 of the 24th WHO Model List (2025) lists acetylsalicylic acid (suppository 50–150 mg; tablet 100–500 mg), ibuprofen (oral liquid 100 mg/5 mL; tablet 200, 400 and 600 mg) and paracetamol (oral liquid 120 mg/5 mL or 125 mg/5 mL and 250 mg/5 mL; suppository 100 and 250 mg; tablet 250, 325 and 500 mg; dispersible tablet 100 and 250 mg). WHO Model List of Essential Medicines, 24th List (2025) — report of the 25th WHO Expert Committee (TRS 1064)
- A strength-confusion warning that matters commercially The Model List itself warns that the presence of both 120 mg/5 mL and 125 mg/5 mL paracetamol oral liquid strengths on the same market would cause confusion in prescribing and dispensing and should be avoided. Country programmes should therefore settle on one strength. WHO Model List of Essential Medicines, 24th List (2025) — report of the 25th WHO Expert Committee (TRS 1064)
Each point above is reproduced because it has a practical consequence for Lysine Acetylsalicylate Injection 7ml:900mg Ampoule: the strength you can register, the pack you can release, or the wording permitted on the label. Your national prescribing information always takes precedence.
Supply & Specification Data for Lysine Acetylsalicylate Injection 7ml:900mg Ampoule
| Product Name | Lysine Acetylsalicylate Injection |
| Specification | 900mg/7mL (equivalent to approximately 500mg acetylsalicylic acid) |
| Dosage Form | Sterile Solution for Injection / Intravenous Infusion |
| Active Ingredient | Lysine Acetylsalicylate (DL-lysine acetylsalicylate, the water-soluble lysine salt of acetylsalicylic acid) |
| Pharmacological Class | Non-Steroidal Anti-Inflammatory Drug (NSAID) / Salicylate / Cyclooxygenase Inhibitor |
| Route of Administration | Intramuscular injection, or slow intravenous injection / intravenous infusion (after dilution). Rapid intravenous bolus injection is NOT recommended. |
| Storage | Store below 25°C, protected from light and moisture. Do not freeze. Keep ampoule in outer carton until use. |
| Therapeutic group | Analgesics & NSAIDs — Analgesics & NSAIDs |
| Manufacturer | Sinophare Bio-technology Co., Ltd. (GMP, China) |
| Documentation supplied | COA, HPLC/GC data, stability data, dossier package |
The same therapeutic range is supplied in several presentations, so one purchase order can cover a mixed requirement: Piroxicam Injection 1ml:10mg, Diclofenac Sodium Injection 3mL:75mg, Paracetamol Injection 500mg/5mL, Ibuprofen Suppository 50mg, Indomethacin Suppository 100mg, Naproxen Suppositories 250mg, Paracetamol Suppository 150mg, Diclofenac Sodium 50mg.
Testing, Monographs & Batch Documentation
Products are manufactured and tested against USP, EP, BP and CP monographs, with incoming raw-material inspection, in-process monitoring and full finished-product testing.
Release testing for Lysine Acetylsalicylate Injection 7ml:900mg Ampoule follows the monograph you nominate — USP, EP, BP or CP. If the presentation is not covered by a monograph, the specification is frozen in writing with your quality team before the batch is manufactured.
Standardised GMP production workshops with an independent R&D laboratory and a complete quality-inspection centre.
The batch record for this product normally includes:
- Testing for dissolution or release profile (solid oral forms)
- Testing for uniformity of dosage units
- Testing for water content and pH where applicable
- Testing for sterility and bacterial endotoxins (parenterals and ophthalmics)
- Testing for microbial limits and preservative efficacy (multi-dose presentations)
- Testing for heavy metals and elemental impurities
COA, HPLC and GC data, DMF and dossier packages, plus registration support documents for national marketing-authorisation filings.
Pack Configuration, Artwork & Shipping Documents
- Pack size: 7mL amber glass ampoule. Non-standard pack sizes can be quoted against your artwork.
- Storage: Store below 25°C, protected from light and moisture. Do not freeze. Keep ampoule in outer carton until use..
- Shelf life: 36 months (unopened). Stability data for the marketed pack is included in the dossier.
- Labelling: we typeset the carton and leaflet in English, Arabic, French, Russian and Spanish and in any further language your market requires, carrying your own brand where the local rules allow.
- Export: commercial invoice, packing list, certificate of origin, GMP certificate, COA and the free-sale certificate issued by the country of manufacture whenever your customs or regulator asks for it.
Dossier, Authority Filings & Tender Documentation
The legal manufacturer named on every document for Lysine Acetylsalicylate Injection 7ml:900mg Ampoule is Sinophare Bio-technology Co., Ltd., DML Number Jin20160068 (medicines) and Jin20160069 (paracetamol API).. The same entity appears on the GMP certificate and on the dossier submitted to your regulator.
- Artwork and mock-up approval pack, showing the carton, label and leaflet exactly as they will be printed for your market.
- Batch manufacturing and packaging records released for inspection on request during supplier audits.
- Re-test or renewal support when the marketing authorisation comes up for variation or renewal.
- CTD dossier modules 1–5 in editable and PDF form, with the finished-product and API sections cross-referenced.
- Site Master File and GMP certificate for the manufacturing workshops.
Lysine Acetylsalicylate Injection 7ml:900mg Ampoule is presented here against non-opioid analgesics and NSAIDs named in the WHO Model List. Inclusion in an essential-medicines list does not authorise sale in any particular country — the marketing authorisation for that market is a separate step.
Buyer Questions about Lysine Acetylsalicylate Injection 7ml:900mg Ampoule
What pack size is available for Lysine Acetylsalicylate Injection 7ml:900mg Ampoule?
Standard commercial packaging for this line is 7mL amber glass ampoule. Alternative pack sizes are produced to your specification and are supported by the corresponding stability data.
What documentation comes with a shipment of Lysine Acetylsalicylate Injection 7ml:900mg Ampoule?
The documentation set for every shipment includes the certificate of analysis (description, identification, assay, related substances), stability data for the marketed pack, and the site GMP certificate. Shelf life: 36 months.
Does the batch documentation for Lysine Acetylsalicylate Injection 7ml:900mg Ampoule support a registration filing?
The documentation set for every shipment includes the certificate of analysis (description, identification, assay, related substances), stability data for the marketed pack, and the site GMP certificate. Shelf life: 36 months. The full CTD dossier and the authority assessment file are supplied as part of a registration order; routine shipments carry the COA and stability data only.
Do you supply paracetamol suppositories?
Yes — 150 mg and paediatric strengths. The Model List specifies suppository strengths of 100 mg and 250 mg, and national formularies frequently add intermediates.
Is diclofenac on the WHO Essential Medicines List?
No. The non-opioid analgesics named in section 2.1 are acetylsalicylic acid, ibuprofen and paracetamol. We supply diclofenac sodium in injectable and capsule form for markets whose national lists include it.
Other Analgesics & NSAIDs Products in This Range
- Piroxicam Injection 1ml:10mg — 1mL
- Diclofenac Sodium Injection 3mL:75mg — 75mg
- Paracetamol Injection 500mg/5mL — 500mg/5mL
- Ibuprofen Suppository 50mg — 50mg
- Indomethacin Suppository 100mg — 100mg
- Naproxen Suppositories 250mg — 250mg
Browse the full Analgesics & NSAIDs range; all Injectables; the complete product catalogue.
Request a Quotation for Lysine Acetylsalicylate Injection 7ml:900mg Ampoule
Tell us the monograph, pack size and quantity required for Lysine Acetylsalicylate Injection 7ml:900mg Ampoule 900mg, together with the destination market, and the quotation will state lead time and the documents that ship with the batch. Samples for registration can be added to the same order.
Sources & Regulatory Notes
Reference information only. The published guidance summarised on this page is quoted for professional and regulatory-context purposes and does not constitute medical advice, a prescribing recommendation or a promotion of any product for a particular indication. Prescribing decisions must follow the approved product information and national treatment guidelines in the market of use.
